Welcome to our dedicated page for Visionary Holdings news (Ticker: GV), a resource for investors and traders seeking the latest updates and insights on Visionary Holdings stock.
Visionary Holdings Inc. (Nasdaq: GV) generates news at the intersection of education, health management, anti-aging medical aesthetics, and regenerative medicine. Company announcements describe an ongoing strategic transformation from a traditional education- and real estate-focused business toward a diversified platform centered on high-end medical aesthetics and big health technology, with AI-enabled education remaining as a supplementary division.
News coverage for GV includes updates on its fiscal year 2025 annual report, where the company outlined progress in its business restructuring and reported initial revenue contributions from emerging health-related businesses. Releases also detail Visionary Holdings' focus on health management initiatives, including gastrointestinal health management and early-stage commercialization efforts in Asia.
Another key stream of news relates to regenerative medicine and stem cell technology. Visionary Holdings has reported a Global Product and Technology Licensing Agreement with Jiangsu Yike Regenerative Medicine Co., Ltd., the creation of Visionary Yike Stemcell Technologies Inc. in Canada, and the launch of a stem cell-based anti-aging product line through its Visionary Health Technology Group Limited subsidiary. These items highlight the company’s emphasis on stem cell therapy, cellular rejuvenation, and premium anti-aging offerings in Asian markets.
Governance and compliance developments are also prominent in GV’s news. The company has announced board renewal, the formation of specialized committees, leadership changes, and auditor appointments, as well as a Nasdaq notification regarding a delayed Form 20-F filing and its plan to regain compliance. Additional releases describe Visionary Holdings’ controlling stake in a joint venture focused on Traditional Chinese Medicine health preservation.
Investors and observers reviewing GV news can expect updates on strategic partnerships, joint ventures, product launches in anti-aging and regenerative medicine, governance changes, and disclosures related to its education and health businesses.
Visionary Holdings (Nasdaq: GV) released its final annual report and audited financial statements for the fiscal year ended March 31, 2025; the Form 20-F filing with the SEC is pending. FY2025 revenue was $5.04M, down 46.2% YoY, with real estate leasing $2.80M, education $1.18M and emerging health businesses $1.06M (≈21.1% of revenue). The company recorded a net loss of $15.75M, including ~$4.70M in asset impairment charges. Total assets were $63.63M and negative working capital was about $54.50M. Management is pursuing equity financing, creditor negotiations, and strategic growth in health management, anti-aging, and premium medical aesthetics while strengthening governance.
Visionary Holdings (Nasdaq: GV) released its finalized annual report and audited financial statements for the fiscal year ended March 31, 2025; Form 20-F filing with the SEC is pending.
Key metrics: FY2025 revenue $5.04M (-46.2% YoY), net loss $15.75M, emerging health businesses revenue $1.06M (~21.1% of total), asset impairment ~$4.70M, and negative working capital ~$54.50M. Management cites transformation investments, financing pressures, creditor negotiations, and plans to pursue health management, anti-aging, premium medical aesthetics, and AI education initiatives.
Visionary Holdings (Nasdaq: GV) filed its Annual Report for fiscal 2025 (year ended Mar 31, 2025) outlining a strategic shift from education and real estate toward health management, anti-aging, and premium medical aesthetics alongside an AI-enabled education business. Total revenue was USD 5.04 million (-46.2% YoY); emerging health businesses contributed ~21.1% of revenue. The company reported a net loss of USD 15.75 million, including ~USD 4.70 million of asset impairment charges, and cited ~USD 54.50 million negative working capital and ongoing liquidity pressures. Management plans further commercialization, strategic collaborations, governance enhancements, and potential financings.
Visionary Holdings (GV) announced governance changes, a strategic pivot to anti-aging high-end medical aesthetics, two September 2025 partnerships, and a timeline for its annual report filing.
Key facts: a new nine-member Board was elected on October 29, 2025; Xiyong Hou named CEO with Jun Huang as Co-CEO; Assentsure PAC reappointed auditor for 2025-2026; partnerships with Jiangsu Yike Regenerative Medicine (global R&D cooperation) and a joint venture with Anhui Weikang Kangling to build an anti-aging health center in Toronto; draft Form 20-F for year ended March 31, 2025 is under final review and expected filed on or before January 12, 2026.
Visionary Holdings (Nasdaq: GV) appointed Wenxuan Cai as CEO of its health technology subsidiary GV Hong Kong, effective Dec 30, 2025, and established a wholly owned Nanjing sales entity focused on regional sales and market development.
The company says this completes a fully integrated commercial structure across strategy, products and sales execution, marking a shift from strategic positioning to active, on-the-ground revenue generation in cellular rejuvenation and aesthetic treatment markets across Asia.
Visionary Holdings (Nasdaq: GV) announced on Nov 10, 2025 the commercial launch of a medical-grade stem cell anti-aging product line via its Hong Kong subsidiary, targeting the Chinese mainland, Hong Kong and Singapore with later expansion planned to Southeast Asia and North America.
GV said it has integrated a global technology licensing agreement with Jiangsu Yike Regenerative Medicine into three core product packages: the flagship Life Rejuvenation Program (mesenchymal stem cells, NK cell therapy, AI diagnostics), a Precision Repair Package with DFPP blood purification, and a Premium Personalized Program including full-genome sequencing and annual customized management.
Planned commercialization steps include a joint-venture production/clinical base, cross-border sales and branded clinic partnerships to support localized manufacturing and market rollout.
Visionary Holdings (NASDAQ: GV) held its First Meeting of the Fourth Board of Directors on November 3, 2025 and unanimously adopted governance resolutions to standardize oversight and operations.
The board elected William T. Chai as Chairman and installed a senior management team: Xiyong Hou (CEO), Jun Huang (Co-CEO), Robert Jay Lees (COO) and Xiaolan Liu (CFO). The company also formed four specialized committees (Audit, Nomination, Compensation, Investment) and adopted committee rules, job descriptions, and company secretary work rules to clarify responsibilities and strengthen compliance.
Resolutions were disclosed via the company website and NASDAQ within 48 hours, emphasizing a focus on high-end stem cell aesthetics and big health technology strategy.
Visionary Holdings (NASDAQ:GV) held its 2025 Annual General Meeting on Oct 31, 2025, with 97.79% of voting rights represented. Shareholders approved a 16-member 4th Session Board slate (9 elected directors named) to serve through the 2026 AGM, reappointed Assentsure PAC as auditor for the Apr 1, 2025–Mar 31, 2026 year, and approved the 2024–2025 financial and board reports. Reported metrics: core businesses contributed 78% of revenue, new big-health net profit grew 100% YoY, total assets were USD 68,792 thousand, and the asset‑liability ratio was 80%. The first board meeting is scheduled for Nov 3, 2025.
Visionary Holdings (Nasdaq: GV) received a Nasdaq Listing Qualifications notice for failure to timely file its Annual Report on Form 20-F for the fiscal year ended March 31, 2025. The notice, dated August 5, 2025, cites noncompliance with Nasdaq Listing Rule 5250(c)(1) but has no immediate effect on the listing or trading of the company's common shares on the Nasdaq Capital Market. The company had a 60-calendar-day period to submit a compliance plan and filed that plan on October 6, 2025. Visionary says it is working with its independent auditor to complete the audit and file the Form 20-F as soon as possible and remains committed to restoring full reporting compliance and maintaining its Nasdaq listing.
Visionary Holdings (Nasdaq: GV) announced on October 22, 2025 a strategic cooperation with Jiangsu Yike to form Visionary Yike Stemcell Technologies, a Canada-based joint venture focused on stem cell R&D, clinical application, manufacturing and global commercialization.
GV will hold 85% and Yike 15%. The JV may be headquartered at GV's Toronto property (95–105 Moatfield Drive, ~40,000 sqm) and will explore cleanrooms, low-temperature biostorage, and production infrastructure. Initial targets include stem cell therapy, immune cell engineering, and AI-supported anti-aging diagnostics with a stated focus on Type 1 and Type 2 diabetes; clinical evidence so far is described as preclinical/exploratory. Development is subject to regulatory, financing, and operational planning.